---
title: "Biosig Tech | 10-Q: FY2025 Q2 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/253267141.md"
datetime: "2025-08-15T20:54:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/253267141.md)
  - [en](https://longbridge.com/en/news/253267141.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/253267141.md)
generator: "portal-rs"
---

# Biosig Tech | 10-Q: FY2025 Q2 Revenue: USD 0

Revenue: As of FY2025 Q2, the actual value is USD 0.

EPS: As of FY2025 Q2, the actual value is USD -0.74.

EBIT: As of FY2025 Q2, the actual value is USD -20.37 K.

### Segment Revenue

-   Revenue for the three months ended June 30, 2025, was $0, compared to $13 for the same period in 2024. For the six months ended June 30, 2025, revenue was $0, compared to $27 in 2024.

### Operational Metrics

-   **Net Loss**: For the three months ended June 30, 2025, the net loss was -$20,368, compared to -$3,911 for the same period in 2024. For the six months ended June 30, 2025, the net loss was -$23,169, compared to -$7,326 in 2024.
-   **Operating Expenses**: Total operating expenses for the three months ended June 30, 2025, were $20,365, compared to $5,305 for the same period in 2024. For the six months ended June 30, 2025, operating expenses were $23,350, compared to $8,756 in 2024.
-   **General and Administrative Expenses**: For the three months ended June 30, 2025, these expenses were $19,792, an increase from $4,914 in 2024. For the six months ended June 30, 2025, expenses were $22,748, up from $7,796 in 2024.

### Cash Flow

-   **Operating Cash Flow**: Net cash used in operating activities for the six months ended June 30, 2025, was -$2,393, compared to -$2,795 in 2024.
-   **Investing Cash Flow**: Net cash provided by investing activities was $366 for the six months ended June 30, 2025.
-   **Financing Cash Flow**: Net cash provided by financing activities was $4,700 for the six months ended June 30, 2025.

### Unique Metrics

-   **Stock-Based Compensation**: For the three months ended June 30, 2025, stock-based compensation was $12.1 million, compared to $4.3 million in 2024. For the six months ended June 30, 2025, it was $14.2 million, compared to $5.4 million in 2024.

### Future Outlook and Strategy

-   **Core Business Focus**: The company is focusing on the commercialization of the PURE EP™ Platform and the development of new product candidates. It is also working on the integration and scaling of Streamex’s tokenization platform and digital asset infrastructure.
-   **Non-Core Business**: The company is developing real-world asset (RWA) tokenization solutions, including commodities-on-chain initiatives, through its acquisition of Streamex.
-   **Priority**: The company is actively exploring various funding sources, including public or private equity offerings, strategic partnerships, and government grants, to support its operations and strategic initiatives.

### Related Stocks

- [BSGM.US](https://longbridge.com/en/quote/BSGM.US.md)
- [STEX.US](https://longbridge.com/en/quote/STEX.US.md)

## Related News & Research

- [STEX: First revenue from tokenized gold, $41.8M liquidity, and new product launches drive growth](https://longbridge.com/en/news/295977814.md)
- [Streamex adds Inspira Financial as custodian for GLDY Class B shares](https://longbridge.com/en/news/293334676.md)
- [Streamex teams with Wintermute to provide 24/7 instant liquidity for GLDY token](https://longbridge.com/en/news/293603089.md)
- [Streamex launches share buyback of up to 10 million shares at up to $2 each](https://longbridge.com/en/news/291925209.md)
- [Biosig Technologies (NASDAQ:STEX) CIO Mitchell Young Williams Sells 263,863 Shares](https://longbridge.com/en/news/285132932.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**